SCHEMBL8397161

SCHEMBL8397161

CCNCc1ccc(CN)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 3/20 0.47
HRH3 Q9Y5N1 2/20 0.46
ANPEP P15144 1/20 0.46
ERAP2 Q6P179 1/20 0.46
LOXL2 Q9Y4K0 4/20 0.44
PSIP1 O75475 1/20 0.43
LMNA P02545 1/20 0.43
ABAT P80404 1/20 0.42
HRH4 Q9H3N8 1/20 0.41
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
PARP1 P09874 1/20 0.38
PARP2 Q9UGN5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9180552 0.87 LMNA (0.52) HRH3LMNAHRH4CYP1A2CYP2D6
SCHEMBL8500622 0.83 PNMT (0.45) LOXL2CYP1A2CYP2D6CYP2C9TSHR
SCHEMBL18235915 0.82 HRH3 (0.52) TPSAB1HRH3ANPEPERAP2LOXL2
SCHEMBL12074568 0.81 GFER (0.46) HRH3ANPEPERAP2LOXL2LMNA
SCHEMBL10052932 0.80 LMNA (0.64) HRH3LMNAHRH4CYP1A2CYP2D6
SCHEMBL18235879 0.79 CHRM2 (0.55) TPSAB1HRH3ANPEPERAP2LOXL2
SCHEMBL17715564 0.79 HRH4 (0.63) HRH3LMNAHRH4CYP1A2CYP2D6
SCHEMBL631818 0.78 CHRM2 (0.59) LMNACYP2D6CYP2C9CYP2C19SMN1; SMN2
Hydrochloric Acid SCHEMBL17710395 0.78 LMNA (0.61) HRH3LMNAHRH4CYP1A2CYP2D6
SCHEMBL21799537 0.77 ANPEP (0.51) TPSAB1HRH3ANPEPERAP2LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116134012-B Method for producing aminomethyl aromatic 三菱瓦斯化学株式会社 2025-05-13 CN disclosed
CN-116134012-A Method for producing aminomethyl aromatic 三菱瓦斯化学株式会社 2023-05-16 CN disclosed
WO-2022019105-A1 METHOD FOR PRODUCING AROMATIC AMINOMETHYL 三菱瓦斯化学株式会社 2022-01-27 WO disclosed
US-11124593-B2 Modified block copolymer, method for producing modified block copolymer, and resin composition ASAHI KASEI KABUSHIKI KAISHA (JP) 2021-09-21 US disclosed
US-20200199282-A1 Modified Block Copolymer, Method for Producing Modified Block Copolymer, and Resin Composition ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-06-25 US disclosed
EP-3623398-A1 MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION Asahi Kasei Kabushiki Kaisha (JP) 2020-03-18 EP disclosed
US-9701628-B2 12-epi pleuromutilins NABRIVA THERAPEUTICS AG (AT) 2017-07-11 US disclosed
US-20160332963-A1 12-EPI PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2016-11-17 US disclosed
WO-2015110481-A1 12-EPI-PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2015-07-30 WO disclosed
US-20070185311-A1 Peptide-Based Multimeric Targeted Contrast Agents EPIX PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed
US-7238341-B2 Peptide-based multimeric targeted contrast agents EPIX PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
US-20050074411-A1 Peptide-based multimeric targeted contrast agents EPIX MEDICAL, INC. A DELAWARE CORPORATION 2005-04-07 US disclosed
EP-0558048-B1 Thermoplastic resin composition IDEMITSU PETROCHEMICAL CO (JP) 1999-07-07 EP disclosed
US-5552480-A BLEND, IMIDIZED ADDITION POLYMER, ENGINEERING PLASTIC, IMPACT STRENGTH IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1996-09-03 US disclosed
EP-0558048-A1 Thermoplastic resin composition IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) 1993-09-01 EP disclosed
US-4142034-A Epoxy resin compositions containing an amine-cyanic acid ester combination curing agent CINCINNATI MILACRON INC. (US) 1979-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185311-A1 Peptide-Based Multimeric Targeted Contrast Agents NGLY1, IAPP, NPPA TPSAB1 2894/4885HRH3 2873/4885ANPEP 26/4885
US-20050074411-A1 Peptide-based multimeric targeted contrast agents NGLY1, IAPP, NPPA TPSAB1 2894/4885HRH3 2873/4885ANPEP 26/4885
US-20160332963-A1 12-EPI PLEUROMUTILINS MLN, TCF12, PLEC TPSAB1 2578/4885HRH3 3275/4885ANPEP 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.